Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new ...

The deal, which will focus first on a COPD therapy GSK believes holds “best-in-class” potential, could ultimately involve a ...

Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

GSK plc has entered into agreements with China-based biotechnology company Hengrui Pharma to develop up to 12 innovative ...

The two companies have entered into an agreement to develop respiratory, immunology, inflammation, and cancer therapies.

Jiangsu Hengrui Pharmaceuticals shares rallied to their highest level in four years – leaping 10% to 62.04 renminbi - after ...

The deal comes as GSK, led by chief exec Emma Walmsley (pictured) focuses on growing its pipeline to offset declining ...

Asian equities were mostly higher overnight as Vietnam and Indonesia outperformed while Japan and India underperformed. Hong ...

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and ...